IP Library › Granted Patent US 11,389,465
Granted Patent B2
US 11,389,465 · App. 16/610,125 · Granted Jul 19, 2022

Phosphorylated hexaacyl disaccharides (PHADs) for treating or preventing infections

Inventors: Edward Sherwood (Nashville, TN); Antonio Hernandez (Franklin, TN); Julia Bohannon (Nashville, TN)
Assignee: Vanderbilt University
A61K31/7016A61K45/06A61P31/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,389,465
App. No.
16/610,125
Granted
Jul 19, 2022
Kind
B2
Abstract

The present disclosure relates to phosphorylated hexaacyl disaccharide (PHAD) compounds, compositions, and methods for treating or preventing infections.

Claims (16)

1. A method for treating or preventing a bacterial infection or a fungal infection, comprising administering to a subject in need thereof a therapeutically effective amount of an active agent, wherein the active agent consists essentially of phosphorylated hexaacyl disaccharide (PHAD), 3-deacyl phosphorylated hexaacyl disaccharide (3D-PHAD), 3-D (6-acyl) phosphorylated hexaacyl disaccharide (3D(6-acyl) PHAD), or a pharmaceutically acceptable salt thereof, wherein the subject is recovering from surgery or the subject is recovering from trauma.

2. The method of claim 1 , wherein the active agent is phosphorylated hexaacyl disaccharide (PHAD).

3. The method of claim 1 , wherein the active agent is 3-deacyl phosphorylated hexaacyl disaccharide (3D-PHAD).

4. The method of claim 1 , wherein the active agent is 3-D (6-acyl) phosphorylated hexaacyl disaccharide (3D(6-acyl) PHAD).

5. The method of claim 1 , wherein the bacterial infection is a multi-drug resistant strain.

6. The method of claim 1 , wherein the bacterial infection is selected from Pseudomonas aeruginosa or Staphylococcus aureus.

7. The method of claim 1 , wherein the bacterial infection is a gram-negative bacteria.

8. The method of claim 1 , wherein the trauma is a burn.

9. The method of claim 1 , wherein the fungal infection is Candida albicans.

10. A method for treating or preventing a bacterial infection or a fungal infection, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an active agent, wherein the active agent consists essentially of phosphorylated hexaacyl disaccharide (PHAD), 3-deacyl phosphorylated hexaacyl disaccharide (3D-PHAD), 3-D (6-acyl) phosphorylated hexaacyl disaccharide (3D(6-acyl) PHAD), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein the subject is recovering from surgery or the subject is recovering from trauma.

11. The method of claim 10 , wherein the active agent is phosphorylated hexaacyl disaccharide (PHAD).

12. The method of claim 10 , wherein the active agent is 3-deacyl phosphorylated hexaacyl disaccharide (3D-PHAD).

13. The method of claim 10 , wherein the active agent is 3-D (6-acyl) phosphorylated hexaacyl disaccharide (3D(6-acyl) PHAD).

14. The method of claim 10 , wherein the bacterial infection is a multi-drug resistant strain.

15. The method of claim 10 , wherein the bacterial infection is selected from Pseudomonas aeruginosa or Staphylococcus aureus.

16. The method of claim 10 , wherein the bacterial infection is a gram-negative bacteria.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2019
From: SHERWOOD, EDWARD; HERNANDEZ, ANTONIO; BOHANNON, JULIA
To: VANDERBILT UNIVERSITY
Reel/Frame 050997/0467 →
Continuity (2)
Provisional Application 62492451 · May 1, 2017
Related Publication 20200085850A1 · Mar 19, 2020